AVEO Key Stats
- Glancy Binkow & Goldberg Announces Lead Plaintiff Deadline In The Class Action L... Jun 17
- Aveo Pharma Hanging By A Thread Jun 16
- Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Aveo ... Jun 14
- CRL for AVEO/ALPMY's Tivozanib - Analyst Blog Zacks Jun 12
- CRL for AVEO/ALPMY's Tivozanib Jun 12
- Law Offices of Todd M. Garber Announces Class Action Lawsuit Against AVEO Pharma... Jun 12
- Drug Rejected! Let's Rejoice? Fool Jun 11
- AVEO Pharmaceuticals, Inc. - Special Call Seeking Alpha Jun 11
- AVEO Oncology Announces Complete Response Letter Received for Tivozanib New Drug... Jun 11
- Aveo says FDA refuses to approve cancer drug Jun 10
AVEO Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). AVEO Pharmaceuticals is down 77.59% over the last year vs S&P 500 Total Return up 25.82%, Onyx Pharmaceuticals up 92.95%, and AMAG Pharmaceuticals up 36.81%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for AVEO
Pro Strategies Featuring AVEO
Did AVEO Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
AVEO Pharmaceuticals is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patients’ lives. AVEO’s proprietary Human Response Platform™ provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. AVEO Pharmaceuticals was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. The company was founded by Ronald A. DePinho, Lynda Chin and Kenneth E. Weg on October 19, 2001 and is based in Cambridge, Massachusetts.